Overview of Dr. Gutierrez

As co-chief, Thoracic Oncology, and director of the Phase 1 Program, I specialize in bringing Phase 1 clinical trials to cancer patients treated at John Theurer Cancer Center. The approximately 40 Phase 1 trials currently in place are focused on immunotherapy, targeted therapies, and cell technologies such as CAR-T therapy, which engineers T-cells to target cancer.

Education & Training

• National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000

• Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996

• Pontifical Xavierian UniversityClass of 1991

Certifications & Licensure

• NJ State Medical License 2011 - 2025

• NY State Medical License 2021 - 2024

• FL State Medical License 2000 - 2014

• American Board of Internal Medicine Internal Medicine
• American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

• CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

• Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

  Andrew Ip, Alessandra Petrillo, Alexandra Della Pia, Geeny G Lee, Sarvarinder Gill, Tony Varughese, Joshua Zenreich, Martin Gutierrez, Jiayu Zhang, Jaeil Ahn, Vishnu B...> ;Leukemia & Lymphoma. 2023 Dec 1
• 10 citations

  Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.

  Shubham Pant, Martin Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A Reardon, Christophe Massard, Anna Minchom, Iwona Lugowska, Omar...> ;The Lancet. Oncology. 2023 Aug 1
• 2 citations

  Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

  Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne W Y Chiu, Jong-Seok Lee, James Chih-...> ;Nature Medicine. 2023 Jul 1
• Join now to see all

Lectures

• Utilization of next generation sequencing (NGS) and rates of undergenotyping in patients with metastatic colon cancer (mCC) treated at academic and community centers i... 

  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

• Rates of genotyping for , , , microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications. 

  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

• Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study. 

  ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
• Join now to see all

Press Mentions

• Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of CancerSeptember 5th, 2022

• Molecular Tumor Testing Transformative, yet 'Under-Optimized'July 23rd, 2021

• NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19th, 2021

• Join now to see all

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  AmeriHealth Direct POS
  Amerihealth HMO
  AmeriHealth PPO
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  First Health PPO
  GHI PPO
  

  Great West PPO
  Horizon BCBS Direct Access
  Horizon BCBS HMO
  Horizon BCBS POS
  Horizon BCBS PPO
  Oxford Health Freedom
  Oxford Health Liberty
  QualCare HMO
  QualCare PPO
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment